Cargando…

Impact of proton therapy on antitumor immune response

Radiotherapy delivered using photons induces an immune response that leads to modulation of the tumor microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors in association with photon radiotherapy. At present, there is no publication on the radio-induced immune respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirjolet, Céline, Nicol, Anaïs, Limagne, Emeric, Mura, Carole, Richard, Corentin, Morgand, Véronique, Rousseau, Marc, Boidot, Romain, Ghiringhelli, François, Noel, Georges, Burckel, Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241828/
https://www.ncbi.nlm.nih.gov/pubmed/34188135
http://dx.doi.org/10.1038/s41598-021-92942-1
_version_ 1783715497583312896
author Mirjolet, Céline
Nicol, Anaïs
Limagne, Emeric
Mura, Carole
Richard, Corentin
Morgand, Véronique
Rousseau, Marc
Boidot, Romain
Ghiringhelli, François
Noel, Georges
Burckel, Hélène
author_facet Mirjolet, Céline
Nicol, Anaïs
Limagne, Emeric
Mura, Carole
Richard, Corentin
Morgand, Véronique
Rousseau, Marc
Boidot, Romain
Ghiringhelli, François
Noel, Georges
Burckel, Hélène
author_sort Mirjolet, Céline
collection PubMed
description Radiotherapy delivered using photons induces an immune response that leads to modulation of the tumor microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors in association with photon radiotherapy. At present, there is no publication on the radio-induced immune response after proton therapy. Balb/c mice bearing subcutaneous CT26 colon tumors were irradiated by a single fraction of 16.4 Gy using a proton beam extracted from a TR24 cyclotron. RNA sequencing analysis was assessed at 3 days post-treatment. Proton therapy immune response was monitored by flow cytometry using several panels (lymphoid, myeloid cells, lymphoid cytokines) at 7 and 14 days post-irradiation. RNA-Seq functional profiling identified a large number of GO categories linked to “immune response” and “interferon signaling”. Immunomonitoring evaluation showed induced tumor infiltration by immune cells. This is the first study showing the effect of proton therapy on immune response. These interesting results provide a sound basis to assess the efficacy of a combination of proton therapy and immune checkpoint inhibitors.
format Online
Article
Text
id pubmed-8241828
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82418282021-07-06 Impact of proton therapy on antitumor immune response Mirjolet, Céline Nicol, Anaïs Limagne, Emeric Mura, Carole Richard, Corentin Morgand, Véronique Rousseau, Marc Boidot, Romain Ghiringhelli, François Noel, Georges Burckel, Hélène Sci Rep Article Radiotherapy delivered using photons induces an immune response that leads to modulation of the tumor microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors in association with photon radiotherapy. At present, there is no publication on the radio-induced immune response after proton therapy. Balb/c mice bearing subcutaneous CT26 colon tumors were irradiated by a single fraction of 16.4 Gy using a proton beam extracted from a TR24 cyclotron. RNA sequencing analysis was assessed at 3 days post-treatment. Proton therapy immune response was monitored by flow cytometry using several panels (lymphoid, myeloid cells, lymphoid cytokines) at 7 and 14 days post-irradiation. RNA-Seq functional profiling identified a large number of GO categories linked to “immune response” and “interferon signaling”. Immunomonitoring evaluation showed induced tumor infiltration by immune cells. This is the first study showing the effect of proton therapy on immune response. These interesting results provide a sound basis to assess the efficacy of a combination of proton therapy and immune checkpoint inhibitors. Nature Publishing Group UK 2021-06-29 /pmc/articles/PMC8241828/ /pubmed/34188135 http://dx.doi.org/10.1038/s41598-021-92942-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mirjolet, Céline
Nicol, Anaïs
Limagne, Emeric
Mura, Carole
Richard, Corentin
Morgand, Véronique
Rousseau, Marc
Boidot, Romain
Ghiringhelli, François
Noel, Georges
Burckel, Hélène
Impact of proton therapy on antitumor immune response
title Impact of proton therapy on antitumor immune response
title_full Impact of proton therapy on antitumor immune response
title_fullStr Impact of proton therapy on antitumor immune response
title_full_unstemmed Impact of proton therapy on antitumor immune response
title_short Impact of proton therapy on antitumor immune response
title_sort impact of proton therapy on antitumor immune response
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241828/
https://www.ncbi.nlm.nih.gov/pubmed/34188135
http://dx.doi.org/10.1038/s41598-021-92942-1
work_keys_str_mv AT mirjoletceline impactofprotontherapyonantitumorimmuneresponse
AT nicolanais impactofprotontherapyonantitumorimmuneresponse
AT limagneemeric impactofprotontherapyonantitumorimmuneresponse
AT muracarole impactofprotontherapyonantitumorimmuneresponse
AT richardcorentin impactofprotontherapyonantitumorimmuneresponse
AT morgandveronique impactofprotontherapyonantitumorimmuneresponse
AT rousseaumarc impactofprotontherapyonantitumorimmuneresponse
AT boidotromain impactofprotontherapyonantitumorimmuneresponse
AT ghiringhellifrancois impactofprotontherapyonantitumorimmuneresponse
AT noelgeorges impactofprotontherapyonantitumorimmuneresponse
AT burckelhelene impactofprotontherapyonantitumorimmuneresponse